Replies to post #119006 on Coffee Sipping Big Board Stocks

[EZ2]

OMG ~~~~ Just got confirmation from FID
on very first MRD.

damn, how painful is that TAX take-out now after all the years
of just sitting! :-(

I'm praying TRUMP's NEW "tax plan" will provide some timely and
less painful trail riding now !!!

S
H
I
T !!!!!!!!!


One parting word: ROTH

[EZ2]

Microsoft's stock gains 0.3%, hits all-time intraday high of $69.14 earlier
MARKETWATCH 9:48 AM ET 4/28/2017

(END) Dow Jones Newswires
04-28-170948ET
Copyright (c) 2017 Dow Jones & Company, Inc.

[EZ2]

Just snatched 500 shares of RIG ~~~~

hope I'm not late! ;-)

(($11.01))

[EZ2]

Exact Sciences to participate in Bank of America Merrill Lynch Healthcare Conference

PR NEWSWIRE 6:00 AM ET 5/1/2017
Symbol Last Price Change
EXAS 30.52 +0.51 (+1.7%)
QUOTES AS OF 09:43:00 AM ET 05/01/2017


MADISON, Wis. , May 1, 2017 /PRNewswire/ -- Exact Sciences Corp. today announced that the company will participate in the Bank of America Merrill Lynch 2017 Healthcare Conference in Las Vegas.



Kevin Conroy , Exact Sciences'(EXAS) chairman and CEO, and Jeff Elliott, the company's chief financial officer, will participate in a fireside chat at the conference on Tuesday, May 16 at 11:20 a.m. PT.

A live webcast of the event will be available through the company's website at www.exactsciences.com. An archived webcast will be available following the conclusion of the fireside chat.

About Exact Sciences Corp.(EXAS)

Exact Sciences Corp. (EXAS) is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer. The company has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of colorectal cancer. Cologuard is included in the American Cancer Society's (2014) colorectal cancer screening guidelines and the recommendations of the U.S. Preventive Services Task Force (2016). Stool DNA is included in the combined screening guidelines of the American Cancer Society/U.S. Multi-Society Task Force/American College of Radiology (2008) and the American College of Gastroenterology guidelines (2009).

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. All statements other than statements of historical facts included in this news release regarding our strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, anticipated results of our sales and marketing efforts, expectations concerning payer reimbursement and the anticipated results of our product development efforts. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; our ability to meet demand for our products and services; the willingness of health insurance companies and other payers to cover Cologuard and reimburse us for our performance of the Cologuard test; the amount and nature of competition from other cancer screening products and services; the effects of the adoption, modification or repeal of any healthcare reform law, rule, order, interpretation or policy; the effects of changes in healthcare pricing, coverage and reimbursement; recommendations, guidelines and quality metrics issued by various organizations such as the U.S. Preventive Services Task Force, the American Cancer Society, and the National Committee for Quality Assurance regarding cancer screening or our products and services; our ability to successfully develop new products and services; our success establishing and maintaining collaborative, licensing and supplier arrangements; our ability to maintain regulatory approvals and comply with applicable regulations; and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Report(s) on Form 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contact:
Megan Reiss
Exact Sciences Corp. (EXAS)
Investor Relations Analyst
[e-mail]
608-535-8815

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/exact-sciences-to-participate-in-bank-of-america-merrill-lynch-healthcare-conference-300448429.html

SOURCE EXACT SCIENCES CORP(EXAS)

[EZ2]

Exact Sciences shares soar as United Healthcare says it will cover colon cancer test
KNIGHT RIDDER/TRIBUNE 1:07 PM ET 5/31/2017
Symbol Last Price Change
EXAS 36.05 +3.4 (+10.41%)
QUOTES AS OF 01:58:11 PM ET 05/31/2017
May 31--Shares of Madison-based Exact Sciences Corp.(EXAS) are up 10% in Wednesday trading after United Healthcare said it would cover the company's Cologuard colon cancer screening test, effective July 1.

Exact Sciences' (EXAS) shares posted the gains on a day when major stock market indexes are all trending lower.

The company declined to comment on United Healthcare's decision, which was announced Tuesday in what the insurer calls a "medical policy update bulletin."

United Healthcare's networks include 1 million physicians and other health care professionals, as well as 6,000 hospitals across the United States.

Cologuard is a cancer screening tool for adults 50 years or older who are at average risk for colorectal cancer.

In late April, Exact Sciences Corp.(EXAS) said it generated revenue of $48.4 million and completed approximately 100,000 Cologuard tests during the quarter ended March 31.

First-quarter 2017 revenue and completed Cologuard test volume grew 226% and 150% from the same period of 2016, respectively, the company said.

For the first quarter of 2017, Exact Sciences(EXAS) reported a net loss of $34.9 million, or 32 cents per share. The company reported a net loss of $47.5 million, or 49 cents per share, for the same period of 2016.

[**D*A**]

No wonder you have EJ handle your trades now. LOL

Wow- over $30 now. Hard to believe I was happy selling at $8.90 last year, lol

[EZ2]

Here's to you.....SUPER DAD ! :-D